JPRN-UMIN000006911招募中2 期
Randomized Phase II study of Bevacizumab with SOX versus Bevacizumab with XELOX as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1 and CPT-11 - Randomized Phase II study of Bevacizumab with SOX versus Bevacizumab with XELOX as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1 and CPT-11
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) History of severe allergy (2) Pregnant or lactating women or women of childbearing potential (3) Severe infectious disease (4) Serious complication (e.g. interstitial pneumonia or pulmonary fibrosis, kidney injury, hepatic failure, uncontrolled diabetes mellitus, uncontrolled hypertension) (5) Comorbidity or history of heart failure (6) Peptic ulcers (7) Peripheral neuropathy (8) Severe diarrhea (9) Massive ascites or pleural effusion requiring treatment (10) Metastasis to the CNS (11) Current or previous (within the last 6 months) history of GI perforation (12) Previous history of thromboembolism, cerebral infarction, pulmonary infarction, interstitial pneumonia or hemoptysis (=> 2.5ml) (13) Any surgical treatments within 28 days (14) Evidence of bleeding diathesis or coagulopathy (15) Ongoing treatment with anticoagulant or aspirin (> 325mg/day) (16) Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ (17) Under coutinuous steroid administration (18) Administration contraindication of L-OHP, Bevacizumab, S-1 or Capecitabine (19) Presence of severe colorectal stricture (20) Any other cases who are regarded as inadequate for study enrollment by the investigator
研究者
相似试验
已完成
2 期
Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancerMetastatic colorectal cancerJPRN-UMIN000005199Tsuchiura kyodo general hospital33
招募中
2 期
Multicenter Phese II Study of SOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral S-1 plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerCnresectable metastatic or recurrent colorectal cancerJPRN-UMIN000011680Chubu Clinical Oncology Group40
进行中（未招募）
不适用
Marker Evaluation for Avastin Research in colorectal cancerEUCTR2011-004755-39-EEGenentech, Inc.360
进行中（未招募）
1 期
Marker Evaluation for Avastin Research in colorectal cancerMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2011-004755-39-IEGenentech, Inc.360
进行中（未招募）
1 期
Marker Evaluation for Avastin Research in colorectal cancerMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-004755-39-PTGenentech, Inc.360